摘要
基质金属蛋白酶是一类锌离子和钙离子依赖的蛋白水解酶,能够降解细胞外基质和基膜,在介导肿瘤血管新生、转移和侵袭等过程中发挥重要作用,基质金属蛋白酶抑制剂已成为当前抗肿瘤新药研发的热点之一。总结基质金属蛋白酶抑制剂用于抗肿瘤治疗的临床研究进展,为其进一步研究与应用提供参考。
Matrix metalloproteinases(MMPs) are a group of zinc and calcium dependent proteolytic enzymes that degrade extracellular matrix and basement membrane. They play very important roles in the processes of tumor angiogenesis, metastasis and invasion. MMP inhibitors(MMPIs) have become the focus of anticancer agents R&D. This paper reviewed the progress in clinical development of MMPIs as anticancer agents, so as to provide references for their further investigation and application.
作者
韩艳珍
薛建鹏
胡加亮
徐寒梅
HAN Yanzhen, XUE Jianpeng, HU Jialiang, XU Hanmei(Engineering Research Center of Peptide Drug Discovery, China Pharmaceutical University,Nanjing 211198, Chin)
出处
《药学进展》
CAS
2018年第2期129-137,共9页
Progress in Pharmaceutical Sciences
基金
中央高校基本科研项目(No.2016ZPY009)
江苏省自然科学基金青年项目(No.BK20160757)
关键词
基质金属蛋白酶
基质金属蛋白酶抑制剂
选择性
抗肿瘤
临床进展
matrix metalloproteinase
matrix metalloproteinase inhibitor
selectivity
anticancer
clinical development